Pharmacotherapy of treatment-resistant schizophrenia: a clinical perspective

Evidence-based Mental Health
Markus Dold, Stefan Leucht


A significant number of patients with schizophrenia do not respond adequately to an initial antipsychotic trial. As first step within a treatment algorithm for therapy-refractory schizophrenia 'pseudoresistance' should be ruled out (eg, re-evaluation of the diagnosis, comorbidities, compliance and adherence in terms of medication intake, adequate dose and treatment duration, and achievement of sufficient plasma levels). In case of treatment resistance, two strategies that are often used in clinical routine care contain dose increase of the current administered antipsychotic drug (dose escalation, high-dose treatment) and switch to another, new antipsychotic. Although the response rates for both options are generally rather low, we see from the evidence-based perspective a slight advantage of the switching strategy (preferably to an antipsychotic with a different receptor-binding profile) compared to a high-dose treatment. After treatment failures with at least two different antipsychotic drugs, a monotherapy with clozapine is considered to be the treatment option of first choice. At present, pharmacological combination and augmentation strategies cannot be regarded as a generally recommendable evidence-based treatment method. A...Continue Reading


Feb 1, 1993·Acta Psychiatrica Scandinavica·A ShalevH Munitz
Mar 1, 1993·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·H J Möller
Dec 10, 2003·Archives of General Psychiatry·Ofer AgidRobert B Zipursky
Jun 23, 2004·Journal of Clinical Psychopharmacology·John M Davis, Nancy Chen
Jul 6, 2004·Journal of Critical Care·Tasnim SinuffUNKNOWN Department of Medicine, McMaster University
May 3, 2005·The American Journal of Psychiatry·Shitij KapurBarry Jones
Sep 21, 2005·The New England Journal of Medicine·Jeffrey A LiebermanUNKNOWN Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators
Jun 9, 2006·Progress in Neuro-psychopharmacology & Biological Psychiatry·Hitoshi TakahashiHisashi Higuchi
Mar 29, 2007·The Journal of Clinical Psychiatry·Stefan LeuchtJohn M Kane
Apr 26, 2008·Schizophrenia Bulletin·Corrado BarbuiAndrea Cipriani
Dec 4, 2009·Schizophrenia Bulletin·Robert W BuchananUNKNOWN Schizophrenia Patient Outcomes Research Team (PORT)
Apr 3, 2010·The American Journal of Psychiatry·David M GardnerRoss J Baldessarini
Sep 3, 2010·The British Journal of Psychiatry : the Journal of Mental Science·Surendra P SinghKelvin Chan
Jan 14, 2011·The Journal of Clinical Psychiatry·Donald C GoffOliver Freudenreich
Jan 7, 2011·The International Journal of Neuropsychopharmacology·Stefan LeuchtJohn M Davis
Oct 18, 2011·Schizophrenia Research·Takefumi SuzukiDavid C Mamo
Nov 15, 2011·Acta Psychiatrica Scandinavica·D M TaylorJ Nielsen
Dec 22, 2011·The British Journal of Psychiatry : the Journal of Mental Science·Takefumi SuzukiDavid C Mamo
Jan 10, 2012·The Journal of Clinical Psychiatry·Iris E SommerRené S Kahn
May 9, 2012·Expert Opinion on Drug Safety·Juan A GallegoChristoph U Correll
Jun 22, 2012·The International Journal of Neuropsychopharmacology·W Wolfgang Fleischhacker, Hiroyuki Uchida
Jul 28, 2012·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Alkomiet HasanUNKNOWN World Federation of Societies of Biological Psychiatry (WFSBP) Task Force on Treatment Guidelines for Schizophrenia
Oct 5, 2012·The American Journal of Psychiatry·Arsime DemjahaOliver D Howes
Apr 23, 2013·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Markus DoldStefan Leucht
May 25, 2013·Fortschritte der Neurologie-Psychiatrie·S LeuchtJ M Davis
May 28, 2013·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Ofer AgidGary Remington

❮ Previous
Next ❯


Oct 7, 2014·Expert Opinion on Pharmacotherapy·Maria Rosaria A MuscatelloRocco Zoccali
Jul 1, 2014·Expert Opinion on Drug Safety·Felix-Martin Werner, Rafael Coveñas
Jul 1, 2015·Evidence-based Mental Health·Markus Dold, Siegfried Kasper
Mar 15, 2015·Current Opinion in Psychiatry·Seiya MiyamotoW Wolfgang Fleischhacker
May 18, 2016·International Journal of Psychiatry in Clinical Practice·Dominique EndresLudger Tebartz van Elst
Jun 17, 2016·European Psychiatry : the Journal of the Association of European Psychiatrists·J M MoilanenJ Miettunen
Aug 24, 2016·International Journal of Psychiatry in Clinical Practice·María Conchita Ocaña-ZuritaHumberto Nicolini
Nov 7, 2016·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Markus DoldSiegfried Kasper
Dec 21, 2016·Clinical Schizophrenia & Related Psychoses·Edward WoloszynJeffery J Grace
Jan 12, 2017·Culture, Medicine and Psychiatry·Julia E H Brown, Simone Dennis
Sep 18, 2015·Journal of Geriatric Psychiatry and Neurology·Massimiliano BuoliAlfredo Carlo Altamura
Jul 14, 2017·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·Gary RemingtonMichael Teehan
Dec 30, 2017·Indian Journal of Psychological Medicine·Mitesh KumarSubhash Das
May 12, 2018·The Cochrane Database of Systematic Reviews·Myrto T SamaraStefan Leucht
Mar 31, 2018·Therapeutic Drug Monitoring·Donatella MarazzitiLiliana DellʼOsso
Jun 27, 2018·The Journal of ECT·Anne SauvagetGiordano DʼUrso
Nov 27, 2018·Psychiatry and Clinical Neurosciences·Fang-Ling LiChih-Sung Liang
Feb 27, 2019·Health Technology Assessment : HTA·Anthony P MorrisonDavid Kingdon
Oct 11, 2019·Culture, Medicine and Psychiatry·Julia E H Brown
Apr 26, 2020·Journal of Clinical Psychopharmacology·Herbert Y MeltzerMyung A Lee
Dec 21, 2019·The Mental Health Clinician·James L Roerig
May 16, 2019·Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·M V Ivanov, D S Zubov
Jan 1, 2016·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·Jimmy LeeGary Remington
Mar 24, 2017·The Cochrane Database of Systematic Reviews·Sarah BarberAndrea Cipriani
Feb 24, 2017·Frontiers in Psychiatry·Dominique EndresLudger Tebartz van Elst
Jan 18, 2017·Psychiatry Investigation·Hye Sung KimIn Won Chung
May 22, 2018·Frontiers in Psychiatry·Dominique EndresLudger Tebartz van Elst
Aug 7, 2019·Psychiatry·Stavroula Rakitzi, Polyxeni Georgila
Nov 17, 2016·International Journal of Psychiatry in Clinical Practice·Markus Dold, Siegfried Kasper
Dec 22, 2020·Focus : Journal of Life Long Learning in Psychiatry·Steven G PotkinOliver D Howes

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here